Science 37 Named Disruptive Innovator of the Year at DPharm 2015

At the The Conference Forum’s DPharm: Disruptive Innovations to Advance Clinical Trials U.S. conference last week, Science 37 was awarded the Disruptive Innovator of the Year award by a panel of judges composed of pharmaceutical industry experts and patient advocates.

Science 37 Co-founder and CEO Noah Craft, MD PhD said, “The clinical trial process is ripe for disruption, and we are honored to be recognized for our commitment to innovate both technology and processes for better, faster, people-powered science.”

According to a 2013 Tufts Center for the Study of Drug Development report, 37 percent of all clinical trial sites fail to meet their enrollment targets, and more than 10 percent never enroll a single patient. The Clinical Trials Transformation Initiative found top barriers to recruitment include difficulty scheduling or securing transportation for study visits. Such realities highlight the unmet need for people-centered innovation in the clinical trial research space, and for Science 37’s technology-enabled clinical trials management tools.

“Science 37 was the most ‘disruptive’ to the current ways of doing things and had the best potential to increase patients’ involvement in clinical trials,” said patient advocate judge, Jamie Goldfarb.

Dr. Craft stated, “Among the group of very novel companies who participated, we are honored to have received this award. Similar to Airbnb and Uber, we saw a critical need to connect people who were looking for trials with researchers who were looking for patients. We believe that Science 37’s proprietary technology, operating model, and trials management process will unlock access to expert researchers for patients who can benefit from participating in trials, and unlock access to patients for those researchers who struggle to find enough participants for research. The convergence of my previous experiences in clinical research, telemedicine and healthcare technology informed how we built our new platform to accelerate drug development. We are excited to harvest the power of emerging technologies and strategic partnerships to bring safe and effective cures more quickly to patients who are waiting. This recognition from our industry peers is inspiring for our whole team.”

Sarah Krüg, CEO of CANCER101 and Executive Director of The Society for Participatory Medicine, and Chair of the Disruptive Innovator of the Year awards process, stated, “Science 37 is a disruptive innovation that was designed with the patient’s needs in mind, and is uniquely positioned to improve patient access to research by connecting patients securely and conveniently to researchers, regardless of where these patients live. This revolutionary technology will help address the unmet needs of various patient populations, especially those with rare diseases and the underserved.”

The judging panel included:

  • Lori Abrams
, Bristol-Myers Squibb
  • Jamie Goldfarb, Patient Advocate
  • Andreas Koester, Janssen
  • Craig Lipset, Pfizer
  • Paulo Moreira
 EMD Serono
  • Stephanie Petrone, Novartis Oncology
  • Chandra Ramanathan, Bayer AG
  • Katherine Vandebelt
, Eli Lilly and Company

Dr. Craft’s winning presentation concluded with the following video — a moving story of how the Science 37 approach the NORA® mobile technology in a clinical trial helped him participate in the research.